First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: A case report

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1391-1396

  Pietzner, Klaus ^a   Jäger, Michael ^b   Schoberth, Alexandra ^b   Oskay Özcelik, Gülten ^a   Kuhberg, Marc ^a   Lindhofer, Horst ^b,c   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TRION Research GmbH   (Germany)

^c TRION Pharma GmbH   (Germany)

Author keywords

Ascites; Catumaxomab; Peritoneal carcinomatosis; Repeated cycle; Trifunctional antibody

Indexed keywords

CATUMAXOMAB; CD45 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HO 3; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY;

ABDOMINAL PAIN; ABDOMINAL SWELLING; ABLATION THERAPY; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CASE REPORT; CHILL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; LYMPH NODE DISSECTION; MALIGNANT ASCITES; MORTALITY; MULTIPLE CYCLE TREATMENT; NAUSEA; PARACENTESIS; PRIORITY JOURNAL; PUNCTURE; RECURRENT CANCER; RECURRENT DISEASE; REPEATED DRUG DOSE; SENTINEL LYMPH NODE; ASCITES; BREAST TUMOR; CANCER STAGING; LUNG CARCINOMA; METASTASIS; PATHOLOGY; PERITONEUM TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ANTIBODIES, BISPECIFIC; ASCITES; BREAST NEOPLASMS; CARCINOMA, LOBULAR; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PERITONEAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84865054609     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9961-5     Document Type: Article

References (10)

1. Aslam N, Marino C. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001;161(22):2733-7.
2. Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198(6):999-1011.
3. Parsons S, Murawa P, Koralewski P. Intraperitoneal treatment of malignant ascites due to epithelial tumours with catumaxomab. a phase II/III study. J Clin Oncol. 2008;28:3000.
4. Heiss M, Murawa P, Koralewski P, Kolesnik O, Ivanchenko V, Dudnichenko A, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010 (Epub ahead of print).
5. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001;98(8): 2526-34.
6. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83(2): 261-6.
7. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol. 1999;163(3):1246-52.
8. Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti- EpCAM Ã -anti-CD3 antibody: a phase I/II study. Clin Cancer Res. 2007;13(13):3899-905.
9. Heiss M, Ströhlein M, Jäger M, Kimmig R, Burges A, Schoberth A, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer. 2005;117(3):435-43.
10. Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer. 2007;97(3):315-21.